Aim. To study efficacy and safety of dihydropyridine calcium antagonists (CA), and amlodipine, in particular, in patients with arterial hypertension (AH) and chronic obstructive pulmonary disease (COPD). Material and methods. The study included 32 patients with Stage I-II AH and COPD in remission, as well as 27 patients with Stage I-II essential AH without COPD. All participants were administered amlodipine for 12 weeks. At baseline and after 12 weeks of treatment, circadian blood pressure profile (CBPP), echocardiography and lung function (LF) parameters were assessed. Results. In patients with AH and COPD, amlodipine course treatment provided stable 24-hour BP control, decreased BP load, normalized BP circadian rhythm and variability, reduced pulmonary hypertension and pathologic left ventricular remodeling (LVR), improved right ventricular (RV) systolo-diastolic function, as well as LF parameters. Conclusion. Modern dihydropyridine CA, and amlodipine, in particular, can be used as first-line medications for AH correction in COPD patients
